Femoston vs Novofem for Postmenopausal HRT
For a postmenopausal woman without contraindications, Femoston (estradiol 1 mg + dydrogesterone) is the more appropriate choice over Novofem (estradiol 1 mg + norethisterone acetate) due to dydrogesterone's superior safety profile regarding venous thromboembolism and potentially breast cancer risk.
Rationale Based on Progestogen Safety Profile
The critical difference between these two preparations lies in the progestogen component, as both contain identical estradiol doses (1 mg).
Dydrogesterone Advantages (Femoston)
Dydrogesterone demonstrates a more favorable safety profile across multiple domains:
Venous Thromboembolism (VTE): Observational studies show that micronized progesterone and pregnanes (including dydrogesterone) have no effect on VTE risk, whereas norpregnane progestagens like norethisterone cause an additional increase in risk 1. This is particularly important given that VTE is one of the most serious complications of HRT.
Breast Cancer Risk: While evidence remains limited, dydrogesterone may confer advantages in terms of breast cancer risk compared with other progestogens 2. The 2021 guideline notes that among progestins, natural micronized progesterone is first choice, with dydrogesterone listed as a second choice, while norethisterone is mentioned with caution regarding cardiovascular and renal effects 3.
Cardiovascular Profile: Studies comparing estradiol with norethisterone acetate versus other regimens showed worse profiles in terms of blood pressure, renal function, and activation of the renin-angiotensin system 3.
Metabolic Benefits
Femoston provides additional metabolic advantages:
Lipid Profile: Recent comparative data show Femoston significantly increases HDL-C (the "good" cholesterol), whereas Climen (containing a different progestogen) does not. Conversely, norethisterone-containing preparations may increase triglycerides 4.
Insulin Sensitivity: Estradiol-dydrogesterone combinations show beneficial effects on metabolic parameters including insulin, glucose, and body fat distribution 5.
Clinical Application Algorithm
Step 1: Verify No Absolute Contraindications
- No unexplained vaginal bleeding
- No history of breast cancer, VTE, stroke, MI, or active liver disease
- No uncontrolled hypertension (confirmed in your scenario)
Step 2: Assess Additional Risk Factors
- If elevated VTE risk (obesity, family history, thrombophilia): Strongly favor Femoston
- If cardiovascular concerns (diabetes, hypertension, dyslipidemia): Favor Femoston for better lipid and blood pressure profile
- If breast cancer family history: Consider Femoston given potentially lower breast cancer signal
Step 3: Dosing and Monitoring
- Start with standard dose: estradiol 1 mg + dydrogesterone 10 mg (continuous combined regimen for amenorrhea)
- Alternative: sequential regimen if withdrawal bleeding acceptable
- Reassess at 3-6 months for symptom control and tolerability
Important Caveats
Duration of Therapy: Both preparations should be used at the lowest effective dose for the shortest duration necessary. For women starting HRT after age 60 or more than 10 years post-menopause, risks may outweigh benefits 6.
Endometrial Protection: Both dydrogesterone and norethisterone provide adequate endometrial protection when used in appropriate doses. Continuous combined regimens (both hormones daily) provide better protection than sequential regimens and avoid withdrawal bleeding 7.
Individual Variation: While dydrogesterone has a superior safety profile overall, some women may not tolerate it due to side effects (headache, dizziness, abdominal discomfort) 8. In such cases, switching to alternative progestogens may be necessary, but norethisterone would not be the next choice—micronized progesterone would be preferable.
Monitoring Requirements: Persistent irregular bleeding after 6 months requires investigation regardless of which preparation is used. Annual review should assess ongoing need, symptom control, and emergence of any contraindications.
Evidence Quality Note
The recommendation for dydrogesterone over norethisterone is based primarily on observational studies and pharmacological profiles rather than head-to-head randomized trials 3, 1. However, the consistency of findings across multiple safety domains (VTE, cardiovascular, metabolic) and the biological plausibility of these differences support this recommendation. The 2021 guideline explicitly lists micronized progesterone as first choice and dydrogesterone as second choice, with norethisterone mentioned with specific safety concerns 3.